{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 116 of 169', '12. Purwar R, Werfel T, Wittmann M. IL-13-stimulated human keratinocytes preferentially', 'attract CD4+CCR4+ T cells: possible role in atopic dermatitis. J Invest Dermatol.', '2006;126(5):1043-1051.', '13. Oh MH, Oh SY, Lu J, Lou H, Myers AC, Zhu Z, Zheng T. TRPAA1-dependent pruritus in', 'IL-13-induced chronic atopic dermatitis. J Immunol. 2013;191(11):5371-5382.', '14. Zheng T, Oh MH, Oh SY, Schroeder JT, Glick AB, Zhu Z. Transgenic expression of', 'interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest', 'Dermatol. 009;129:742-751.', '15. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two', 'phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016', 'Dec 15;375(24):2335-2348.', '16. May RD, Monk PD, Cohen ES, Manuel D, Dempsey F, Davis NH, et al. Preclinical', 'development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe', 'uncontrolled asthma. Br J Pharmacol. 2012;166(1):177-193.', '17. Thom G, Minter R. Optimization of CAT-354, a therapeutic antibody directed against', 'interleukin-13, using ribosome display. Methods Mol Biol. 2012;805:393-401.', '18. Blanchard C, Mishra A, Saito-Akei H, Monk P, Anderson I, Rothenberg ME. Inhibition of', 'human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-', 'interleukin-13 antibody (CAT-354). Clin Exp Allergy. 2005;35(8):1096-1103.', '19. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and', 'severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol.', '2001;10(1):11-18.', '20. European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the', 'SCORAD index. Consensus report of the European task force on atopic dermatitis.', 'Dermatology. 1993;186(1):23-31.', '21. Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development', \"and initial validation of a new tool for measuring atopic eczema severity from the patients'\", 'perspective. Arch Dermatol. 2004;140(12):1513-1519', '22. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical', 'measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216.', '23. Greiner W, Weijnen T, Nieuwenhuizen M, Oppe S, Badia X, Busschbach J, et al. A single', 'European currency for EQ-5D health states. Results from a six-country study. Eur J Health', 'Econ. 2003;4(3):222-231.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 117 of 169', '24. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand.', '1983;67(6):361-370.', '25. Mansouri Y, Guttman-Yassky E. Immune pathways in atopic dermatitis, and definition of', 'biomarkers through broad and targeted therapeutics. J Clin Med. 2015;4(5):858-873.', '26. Holm S. A simple sequentially rejective multiple test procedure. Scan J Stat.', '1979;6(2):65-70.', '27. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement:', 'updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8:18.', '28. Harmonising Outcome Measures for Eczema (HOME). EASI scoring table for aged 8 and', 'over [homepage on the Internet]. Available from:', 'http://www.nottingham.ac.uk/homeforeczema/index.aspx [cited 21-Nov-2016].', '29. Bancroft AJ, Artis D, Donaldson DD, Sypek JP, Grencis RK. Gastrointestinal nematode', 'expulsion in IL-4 knockout mice is IL-13 dependent. Eur J Immunol. 2000;30(7):2083', '2091.', '30. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR.', 'Validation of a general measure of treatment satisfaction, the Treatment Satisfaction', 'Questionnaire for Medication (TSQM), using a national panel study of chronic disease.', 'Health Qual Life Outcomes. 2004;2:12.', '31. Johansson SGO, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised', 'nomenclature for allergy for global use: report of the Nomenclature Review Committee of', 'the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832-', '836.', '32. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I.', 'Conceptual framework and item selection. Med Care. 1992;30(6):473-83.', '33. European Parliament and Council of The European Union. Directive 2001/20/EC of 4', 'April 2001 on the approximation of the laws, regulations and administrative provisions of', 'the Member States relating to the implementation of good clinical practice in the conduct', 'of clinical trials on medicinal products for human use [2001], article 10.', '34. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol.', '1980;92(Suppl):44-47.', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}